TICKERNERD
Menu
PFEPFEHealthcare · Drug Manufacturers - General

PFE Stock Forecast: Pfizer Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$28
+1.01% on the day

The 28 Wall Street analysts covering Pfizer Inc. hold a median 12-month price target of $28 — -0.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 22 Aug 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$160.0B
Ticker Nerd rank
79 / 100
Median analyst target
$28
Analysts covering
28
Total return, dividends reinvested
1W
+4.8%
1M
+14.5%
YTD
+18.5%
1Y
+16.6%
From 52W high
−0.6%
From 52W low
+27.1%
$22
$28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PFE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pfizer Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
79 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Volatility
96
Quality
92
Accruals
76
Momentum
72
Revisions
61
Issuance
51
Growth
38
Size
2

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (38): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PFE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PFE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$25$30$35Oct 25Jan 26Apr 26Jul 26PFEHigh $36Median $28Low $25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says28 analysts
10 Buy16 Hold2 Sell
Low $25Median $28High $36

The green dot is the last close — the median target sits −0.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 6 moved it down.

DateFirmActionRatingTarget
7 Aug 2026GuggenheimMaintainsBuy$35 → $31
13 July 2026BMO CapitalMaintainsOutperform$34 → $30
13 July 2026BMO CapitalMaintainsOutperform—
13 July 2026GuggenheimMaintainsBuy$36 → $35
13 July 2026GuggenheimMaintainsBuy—
10 July 2026B of A SecuritiesMaintainsNeutral$27 → $26
10 July 2026B of A SecuritiesMaintainsNeutral—
8 July 2026JP MorganMaintainsNeutral$30 → $28
8 July 2026JP MorganMaintainsNeutral—
6 July 2026Cantor FitzgeraldReiteratesNeutral$27
6 July 2026Cantor FitzgeraldReiteratesNeutral—
6 July 2026HSBCDowngradeHold$32 → $28
6 July 2026HSBCDowngradeHold—
10 June 2026RBC CapitalUpgradeSector Perform—
29 Apr 2026CitigroupMaintainsNeutral—
20 Apr 2026RBC CapitalReiteratesUnderperform—
16 Apr 2026CICCInitiatesOutperform—
13 Apr 2026UBSMaintainsNeutral—
10 Apr 2026Morgan StanleyMaintainsEqual-Weight—
9 Apr 2026B of A SecuritiesMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PFE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PFE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.4%
Analysts raising
12
Analysts cutting
6
Fundamentals

Pfizer Inc. (PFE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
36.9×

Cheaper than 21% of US stocks

Price / sales
2.5×

Cheaper than 48% of US stocks

Price / book
1.9×

Cheaper than 49% of US stocks

EV / EBITDA
8.4×

Cheaper than 45% of US stocks

Growth & margins
Revenue growth (YoY)
2.6%

Higher than 33% of US stocks

Earnings growth (YoY)
2.6%

Higher than 39% of US stocks

Gross margin
72.8%

Higher than 85% of US stocks

Operating margin
27.9%

Higher than 86% of US stocks

Net margin
6.8%

Higher than 64% of US stocks

Returns & dividend
Return on equity
5.0%

Higher than 54% of US stocks

Return on assets
5.8%

Higher than 80% of US stocks

Dividend yield
6.1%

Higher than 86% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PFE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
PFEPfizer Inc.$160.0B
79
GILDGilead Sciences, Inc.$181.4B
92
BMYBristol Myers Squibb Co.$136.4B
99
AMGNAmgen, Inc.$236.8B
92
MRKMerck & Co., Inc.$378.6B
83
ABBVAbbVie, Inc.$468.1B
96
JNJJohnson & Johnson$650.8B
92

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pfizer Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PFE news & analysis

Buy 4 Barron's Better Bets (Than T-Bills) Out Of 11 'Safer' August DiviDogs

Seeking Alpha · 22 Aug 2026positive

An analysis identifying four Barron's Better Bets (PFE, VZ, RF, KMI) with "safer" dividends, where yields from a $1,000 investment exceed share prices. Analyst projections suggest top-ten better-bet dividend stocks could deliver an average net gain of 15.46% by August 2027 with volatility about 23% below the market, while five such stocks with negative free cash flow margins were flagged as having unsafe dividends.

Why it matters — PFE watchers would note that Pfizer is explicitly listed among the four safer dividend picks with positive cash flow and yield parity in this analysis, distinguishing it from the five flagged as unsafe.

Prediction: This Is Where Pfizer Stock Will Be in 2030

The Motley Fool · 22 Aug 2026neutral

The Motley Fool published an article predicting where Pfizer's stock will be by 2030, noting that the company faces three notable patent expirations through the end of 2028.

Why it matters — PFE watchers would care because the upcoming patent expirations could affect the company's future revenue streams and growth outlook.

Pfizer: Patient Investors Will Be Rewarded

Seeking Alpha · 21 Aug 2026positive

The article presents Pfizer as significantly undervalued with robust profitability and a forward dividend yield above 6%. It highlights the company's diversified product roadmap and disciplined capital allocation as offsets to loss-of-exclusivity uncertainties and COVID revenue declines, while oncology pipeline progress, bolstered by the Seagen acquisition, is cited as a long-term growth pathway.

Why it matters — A PFE watcher would care because the piece points to financial stability, an above-6% dividend yield, and pipeline and acquisition-driven growth potential amid declining COVID revenue and patent expirations.

Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead

24/7 Wall Street · 20 Aug 2026positive

A 24/7 Wall Street article titled "Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead" highlights strong performances by major dividend-paying stocks, noting that Pfizer has risen 19.3% year to date, alongside Chevron's 38.76% and AbbVie's 19.16% gains.

Why it matters — The article points to Pfizer's solid year-to-date gain and frames it among leading dividend stocks with notable performance, giving PFE watchers a positive snapshot of the company's recent market traction.

Yield Hunters Are Swarming This 6.3%-Dividend Stock—And Big-League Hedge Funds are Quietly Buying the Dip

24/7 Wall Street · 20 Aug 2026positive

Recent 13F filings reveal significant buying activity in Pfizer shares among large hedge funds, with the smart-money crowd showing interest in the company. The stock is noted for offering a 6.3% dividend yield that has attracted yield-seeking investors.

Why it matters — A PFE watcher would care because institutional hedge-fund buying via 13F filings signals growing interest in the stock from the smart-money crowd.

FAQ

Frequently asked questions about PFE stock

What is the PFE stock price forecast for 2026-2027?

The 28 Wall Street analysts covering Pfizer Inc. have a median 12-month price target of $28, with estimates ranging from $25 to $36. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PFE stock a buy right now?

Of the 28 analysts covering Pfizer Inc., 10 rate it a Buy, 16 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Pfizer Inc. 79 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PFE?

As at 22 Aug 2026, Pfizer Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will PFE stock go up?

No one can know that. What the data says: the median 12-month target from 28 analysts implies -0.2% from the last close, and Ticker Nerd's factor model ranks Pfizer Inc. 79 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PFE stock forecast for 2030?

No analyst covering Pfizer Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PFE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $36 over the next 12 months.

How has PFE stock performed over the past year?

Pfizer Inc. returned +16.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pfizer Inc. do?

Pfizer Inc. is a global biopharmaceutical company that develops, manufactures, markets, and distributes medicines and vaccines for patients worldwide.

What is the latest news on PFE?

The most recent item we track (Seeking Alpha, 22 Aug 2026): "Buy 4 Barron's Better Bets (Than T-Bills) Out Of 11 'Safer' August DiviDogs". An analysis identifying four Barron's Better Bets (PFE, VZ, RF, KMI) with "safer" dividends, where yields from a $1,000 investment exceed share prices. Analyst projections suggest top-ten better-bet dividend stocks could deliver an average net gain of 15.46% by August 2027 with volatility about 23% below the market, while five such stocks with negative free cash flow margins were flagged as having unsafe dividends.

Company

About Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical company that develops, manufactures, markets, and distributes medicines and vaccines for patients worldwide. Its current portfolio spans oncology, internal medicine, vaccines, inflammation and immunology, rare diseases, and hospital-based therapies, supported by a broad commercial presence across major healthcare markets. Pfizer also offers consumer health products and continues to operate across both prescription and non-prescription categories through its diversified healthcare platform. The company works with research, regulatory, and healthcare partners to deliver treatments used in primary care, specialty care, and hospital settings. Founded in 1849 and headquartered in New York, Pfizer remains a major name in the pharmaceutical industry, with a role centered on advancing access to established therapies and newly approved medicines across global markets.

CEO Dr. Albert Bourla D.V.M., Ph.D. · 75,000 employees · United States · https://www.pfizer.com